Microba Life Sciences Ltd
MAP
Company Profile
Business description
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are; Testing Services and Supplements which derives key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.
Contact
324 Queen Street
Level 10
BrisbaneQLD4000
AUST: +61 1300974621
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.
stocks
Cheap ASX energy play boasts strong cash flows and balance sheet
Markets appear overly bearish on the company despite the company having attracting growth options.
stocks
Market overreacts to earnings miss from moated ASX retailer
Our forecast recovery is off to a slow start but the sell-off appears to have gone too far.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,207.30 | 32.70 | -0.35% |
CAC 40 | 7,683.85 | 159.19 | -2.03% |
DAX 40 | 24,163.36 | 109.76 | -0.45% |
Dow JONES (US) | 45,282.47 | 349.27 | -0.77% |
FTSE 100 | 9,266.93 | 54.47 | -0.58% |
HKSE | 25,524.92 | 304.99 | -1.18% |
NASDAQ | 21,449.29 | 47.24 | -0.22% |
Nikkei 225 | 42,394.40 | 413.42 | -0.97% |
NZX 50 Index | 12,957.98 | 121.52 | -0.93% |
S&P 500 | 6,439.32 | 27.59 | -0.43% |
S&P/ASX 200 | 8,935.60 | 31.30 | -0.35% |
SSE Composite Index | 3,868.38 | 15.18 | -0.39% |